Metformin/Empagliflozin and Zonisamide Interaction

Drug interaction information between Metformin/Empagliflozin and Zonisamide.

Metformin/Empagliflozin and Zonisamide have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Metformin/Empagliflozin and Zonisamide. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Metformin/Empagliflozin

Biguanide / SGLT2 Combination

Drug B

Zonisamide

Anticonvulsant (Sulfonamide)

How They Interact

Zonisamide can cause an acid buildup in the blood, which increases the risk of a serious condition called metabolic acidosis when taken with metformin.

Metformin/Empagliflozin Also Interacts With

View all Metformin/Empagliflozin interactions →

Frequently Asked Questions

What SPL severity band is on file for Metformin/Empagliflozin + Zonisamide?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Zonisamide has 13 labeled pairs on file vs Metformin/Empagliflozin's 9. In the minor band specifically: Metformin/Empagliflozin has 4 (also Topiramate, Lithium, Phenytoin); Zonisamide has 10 (also Carbamazepine, Empagliflozin, Empagliflozin/Linagliptin, Linagliptin).

What mechanism field is on file for Metformin/Empagliflozin and Zonisamide?

Zonisamide can cause an acid buildup in the blood, which increases the risk of a serious condition called metabolic acidosis when taken with metformin.

Zonisamide's labeled portfolio outnumbers Metformin/Empagliflozin

SPL source-record counts only. This page's band is minor · classes on file: Metformin/Empagliflozin (Biguanide / SGLT2 Combination); Zonisamide (Anticonvulsant (Sulfonamide)).

Metformin/Empagliflozin

0 major · 5 moderate · 4 minor · 9 total

Zonisamide

0 major · 3 moderate · 10 minor · 13 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.